Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Status unconfirmed · Phase 2

Conditions studied: Myelodysplastic Syndrome

In brief

Myelodysplastic syndrome (MDS) is a rare, potentially serious bone marrow disease. Currently available treatments for MDS have been only somewhat beneficial. The purpose of this study is to determine the effects of the medication antithymocyte globulin (ATG) in adults with MDS and to determine which individuals with MDS are most likely to benefit from treatment with ATG.

Key facts

Study ID

NCT00466843

Run by

Office of Rare Diseases (ORD)

People needed

54

Starts

2007-04-01

Expected to finish

2010-02-01

Last updated by the study team

2009-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of MDS that meets International Prognostic Scoring System (IPSS) criteria for low risk, intermediate-1 risk, or intermediate-2 risk. More information about this criterion can be found in the protocol.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
• Willing and able to attend study visits
• Willing to use acceptable forms of contraception prior to study entry and for the duration of the study

You may not qualify if…

• Any serious medical illness that might limit survival to less than 2 years
• Any other uncontrolled condition or illness. More information about this criterion can be found in the protocol.
• Prior anti-lymphocyte serotherapy (received serum from an immunized animal)
• Proliferative chronic myelomonocytic leukemia
• MDS that is caused by radiotherapy, chemotherapy, and/or immunotherapy for cancerous or autoimmune diseases
• Previous or current cancer. More information about this criterion can be found in the protocol.
• Receiving any other investigational agents
• Certain abnormal lab values. More information about this criterion can be found in the protocol.
• History of a grade 2 National Cancer Institute common toxic criteria allergic reaction to rabbit proteins
• Psychiatric illness that might interfere with study participation
• HIV-1 infection
• Pregnancy or breastfeeding

Where it is running

• H. Lee Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Cleveland Clinic Foundation - Case Western University — Cleveland, Ohio, United States (enrolling)
• Penn State University — Hershey, Pennsylvania, United States (enrolling)
• UCLA Oncology Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.